Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
The lancet oncology | 18 Dec 2013
S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, B Grant, DA Richards, M Coleman, WG Wierda, JA Jones, W Zhao, NA Heerema, AJ Johnson, R Izumi, A Hamdy, BY Chang, T Graef, F Clow, JJ Buggy, DF James and JC Byrd
Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection. We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia.
* Data courtesy of Altmetric.com